Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer

NCT00608972 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Doxil
DRUG: Carboplatin
DRUG: Bevacizumab

Sponsor

Rutgers, The State University of New Jersey

Collaborators

[object Object]
[object Object]